Approval · Notice of Compliance 33239 · 2024
FLUZONE: Notice of Compliance 33239
Issued May 10, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33239
- Date
- May 10, 2024
- Company
- Sanofi Pasteur LimitedSwiftwater, Pennsylvania, United States
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative - Change in Product Ownership
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FLUZONE | Not yet assigned | — |
Medicinal ingredients
- HAEMAGGLUTININ-STRAIN A(H1N1) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN A(H3N2) 15 MCG per 0.5ML
- HAEMAGGLUTININ-STRAIN B 15 MCG per 0.5ML